Publication | Open Access
Targeting STT3A produces an anti-tumor effect in lung adenocarcinoma by blocking the MAPK and PI3K/AKT signaling pathway
16
Citations
26
References
2022
Year
STT3A promotes LUAD progression via the MAPK and PI3K/AKT signaling pathways and could serve as a novel prognostic biomarker and potential therapeutic target for LUAD patients.
| Year | Citations | |
|---|---|---|
Page 1
Page 1